
==== Front
Blood Adv
Blood Adv
Blood Advances
2473-9529
2473-9537
The American Society of Hematology

S2473-9529(24)00309-4
10.1182/bloodadvances.2024013477
Inside Blood Advances
Donor safety confirmed
Szer Jeff
Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia
13 8 2024
13 8 2024
13 8 2024
8 15 41944195
© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
2024
The American Society of Hematology
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
==== Body
pmcIn this issue of Blood Advances, after almost 3 decades, Stefanski et al1 from the National Marrow Donor Program (NMDP) have demonstrated to the stem cell transplant and general hematology community that the use of filgrastim for stem cell mobilization is safe for volunteer hematopoietic stem cell donors. There was a period of >30 years in which bone marrow, obtained by direct harvesting, was the standard and sometimes the only source of hematopoietic stem cells. The introduction of mobilized blood-derived cells into allogeneic transplantation has resulted in them becoming the preferred and dominant source for transplantation and apheresis becoming the dominant method for stem cell collection, both for family member and unrelated transplants. It is notable that despite the known short-term risks associated with the operating room approach, the long-term safety of bone marrow collection has not been investigated before this current research being done.

This observational research was of a large number of participants compared with most undertaken in transplant studies. It involved 14 530 mobilized peripheral blood stem cell and 7123 bone marrow volunteer, unrelated donors. Its strength was near-universal and prospective data collection. The conclusions are clear and reassuring: myeloid malignancies are not more common in filgrastim-mobilized donors than in bone marrow donors and were very infrequent in both. The incidence of other hematologic and nonhematologic malignancies, autoimmune disease, or thrombosis were not different to that of age- and sex-matched individuals as reported by the Surveillance, Epidemiology, and End Results (SEER) program database.

Arguably, the introduction of filgrastim-mobilized autologous stem cells for autotransplantation in the early 1990s opened this form of therapy to many patients for whom it would otherwise have been not possible and saved many lives. This experience in autologous transplantation eventually led to investigation of the use of these cells in allogeneic donors. For all of this, we can thank the conclusions of the seminal study by Dührsen et al that demonstrated the mobilization of hematopoietic progenitor cells by filgrastim in patients with solid tumors.2 Filgrastim was a relatively new biologic at the time apheresis-based stem cell harvesting commenced, resulting in concern that a bone marrow stimulating cytokine might induce a variety of hematologic malignancies as well as other complications such as autoimmune diseases.3,4 This was of particular concern in volunteer donors. This notion was supported to some extent by in vitro studies suggesting genetic and epigenetic changes in cells induced by filgrastim.5

The methodology in this study by Stefanski used the extensive database developed prospectively by the NMDP for both blood cell and bone marrow donation under a series of investigational new drug trials. The donors were all unrelated volunteers, removing most of the impact of a family history of hematologic malignancy from the analysis, in contrast to the situation that might apply in a family member donor population. The same question in a population of predominantly related donors was addressed in a recent study from the European Group for Blood and Marrow Transplantation,6 which used a normal population as the comparator. It too failed to demonstrate an increase in the risk of malignancy in those donors. In this study of unrelated donors, the SEER database was interrogated as the comparator group for the relative risk of development of malignancy.

The use of allogeneic blood-derived, growth-factor mobilized stem cells, particularly from nonfamily member donors, was based on important early work that demonstrated feasibility as well as optimal regimens for cell collection.7 Currently, mobilized stem cells are by far the commonest source of allogeneic products for transplantation globally, although there are some regional variations.8

The findings of this study should reassure prospective donors that their donation does not come with a significant risk of long-term complications. In the future, it is probable that an increasing number of donors will receive other and newer mobilizing agents such as the chemokine (C-X-C motif) receptor 4 antagonist, plerixafor.9 Ongoing data collection by international registries will be essential to identify any safety signals that might emerge with these new agents. The World Marrow Donor Association has an existing reporting mechanism for any adverse events that may emerge with current and new agents.10 This system is managed by a supervisory committee that can produce global alerts if any unexpected and serious observation in donors is made.

Conflict-of-interest disclosure: J.S. reports advisory committee, consultancy, speaker bureau fees, and travel assistance from Alexion Pharmaceuticals and Sobi Pharmaceuticals; advisory committee with Novartis; and consultancy fees from ADARx Pharmaceuticals, Kira Pharmaceuticals, Samsung Bioepis, and Novartis.
==== Refs
References

1 Stefanski HE Kuxhausen M Bo-Subait S Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim Blood Adv 8 15 2024 4196 4206 38687368
2 Dührsen U Villeval JL Boyd J Kannourakis G Morstyn G Metcalf D Effects of recombinant granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients Blood 72 6 1988 2074 2081 3264199
3 Bennett CL Evens AM Andritsos LA Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the research on adverse drug events and reports (RADAR) project Br J Haematol 135 5 2006 642 650 17054431
4 Vasiliu IM Petri MA Baer AN Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares J Rheumatol 33 9 2006 1878 1880 16832843
5 Nagler A Korenstein-Ilan A Amiel A Avivi L Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells Exp Hematol 32 1 2004 122 130 14725909
6 Cavallaro AM Lilleby K Majolino I Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor Bone Marrow Transplant 25 1 2000 85 89 10654020
7 Grigg AP Roberts AW Raunow H Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers Blood 86 12 1995 4437 4445 8541532
8 Tokaz MC Baldomero H Cowan AJ An analysis of the Worldwide utilization of hematopoietic stem cell transplantation for acute myeloid leukemia Transplant Cell Ther 29 4 2023 279.e1 279.e10
9 Couban S Wong PC Schultz KR The case for plerixafor to replace filgrastim as the optimal agent to mobilize peripheral blood donors for allogeneic hematopoietic cell transplantation Exp Hematol 70 2019 1 9 30428338
10 Shaw BE Chapman J Fechter M Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation Bone Marrow Transplant 48 12 2013 1506 1509 23892330
